For instance, in hematopoietic malignancies and solid tumors, such as acute myeloid leukemia (36), chronic lymphocytic leukemia (37), multiple myeloma (38), bladder cancer (39), and human colorectal carcinoma (17), miR-582 serves as an anti-oncogenic biomarker and can inhibit proliferation and induce apoptosis of these malignant cells by targeting different genes, such as cyclin B2, HNRNPA1, HMGB2 and Rab27a (17, 35–38). This evidence concerns the gene RAB27A and urinary bladder carcinoma.